Unlock instant, AI-driven research and patent intelligence for your innovation.
Application of pharmaceutical composition in preparation of therapeutic drug for tumor insensitive to PD-1 antibody immunotherapy
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of PD-1 and immunotherapy, applied in the field of medicine, can solve the problem of insensitivity of antibody immunotherapy and achieve the effect of inhibiting tumor growth
Pending Publication Date: 2020-09-29
SUN YAT SEN UNIV CANCER CENT
View PDF0 Cites 7 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0005] The present invention aims to solve the problem that some tumor patients are not sensitive to PD-1 antibody immunotherapy, and provides a targeted treatment plan for tumors with primary drug resistance to PD-1 antibody therapy
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0026] Example 1 The influence of key driver genes Fgf3, Fgf4, and Fgf15 in the chromosome 11q13.3 segment on PD-1 antibody treatment
[0027] 1. Experimental materials:
[0028] (1) Tumor cell line: In this experiment, the classic mouse tumorcell line MC38 used in the basic research of immunotherapy was used.
[0029] (2) Experimental mice: C57BL / 6J mice.
[0030] (3) Drug: murine PD-1 antibody, clone number G4C2.
[0033] Tumor cells overexpressing the empty vector and tumor cells overexpressing mouse Fgf3, Fgf4, and Fgf15 were subcutaneously formed in C57BL / 6J mice, and they were divided into two groups:
[0050] Tumor cells overexpressing the empty vector and tumor cells overexpressing mouse Fgf15 were subcutaneously formed into tumors in C57BL / 6J mice, and each was divided into 4 groups:
[0052] (2) Treatment group 1: treated with murine PD-1 antibody;
[0053] (2) Treatment group 2: LY2874455 treatment;
[0054] (2) Treatment group 3: treated with mouse PD-1 antibody combined with LY2874455;
[0055] 3. Experimental steps:
[0056] (1) Construc...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses application of a pharmaceutical composition in preparation of a therapeutic drug for a tumor insensitive to PD-1 antibodyimmunotherapy, and particularly relates to applicationof a PD-1 antibody combined LY2874455 in preparation of a drug for treating a chromosome 11q13.3 segment amplified tumor. Advanced solid tumors include esophageal squamous carcinoma, colorectal cancer, melanoma, head and necksquamous carcinoma or bladder cancer and the like. The anti-PD-1 antibody and LY2874455 combined medication scheme can be used for the tumor which is amplified in the chromosome 11q13.3 segment and is insensitive to PD-1 antibody immunotherapy, and compared with single-drug treatment, tumor growth is remarkably inhibited, so that a patient ineffective to the PD-1 antibody can benefit from the combined therapy.
Description
technical field [0001] The invention belongs to the technical field of medicine. More specifically, it relates to the application of PD-1 antibody combined with LY2874455 in the preparation of drugs for the treatment of tumors insensitive to PD-1 antibody immunotherapy, and the tumor insensitive to PD-1 antibody immunotherapy specifically refers to chromosome 11q13.3 Tumors with segmental amplification. Background technique [0002] Immunotherapy is an emerging tumor treatment method, and PD-1 (programmed cell deathprotein 1) is a common target of immunotherapy. PD-1 is an immunosuppressive receptor mainly expressed on the surface of T cells, B cells, monocytes and NK cells. When activated, PD-1 can activate tumor antigen-specific T cells and promote tumor immune escape. PD-1 antibody can release the immunosuppressive effect of this pathway by competitively binding to PD-1, and restore the anti-tumor immunity of T cells. PD-1 antibody is an immune checkpoint inhibitor, w...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More